135 related articles for article (PubMed ID: 23442031)
1. Cyproheptadine for prevention of neuropsychiatric adverse effects of efavirenz: a randomized clinical trial.
Dabaghzadeh F; Ghaeli P; Khalili H; Alimadadi A; Jafari S; Akhondzadeh S; Khazaeipour Z
AIDS Patient Care STDS; 2013 Mar; 27(3):146-54. PubMed ID: 23442031
[TBL] [Abstract][Full Text] [Related]
2. Potential benefits of cyproheptadine in HIV-positive patients under treatment with antiretroviral drugs including efavirenz.
Dabaghzadeh F; Khalili H; Ghaeli P; Dashti-Khavidaki S
Expert Opin Pharmacother; 2012 Dec; 13(18):2613-24. PubMed ID: 23140169
[TBL] [Abstract][Full Text] [Related]
3. Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study.
Pedrol E; Llibre JM; Tasias M; Currán A; Guardiola JM; Deig E; Guelar A; Martínez-Madrid O; Tikhomirova L; Ramírez R;
HIV Med; 2015 Nov; 16(10):628-34. PubMed ID: 26238151
[TBL] [Abstract][Full Text] [Related]
4. Effect of Valerian in Preventing Neuropsychiatric Adverse Effects of Efavirenz in HIV-Positive Patients: A Pilot Randomized, Placebo-Controlled Clinical Trial.
Ahmadi M; Khalili H; Abbasian L; Ghaeli P
Ann Pharmacother; 2017 Jun; 51(6):457-464. PubMed ID: 28478716
[TBL] [Abstract][Full Text] [Related]
5. Depression and Suicidal Ideation Among HIV-Infected Adults Receiving Efavirenz Versus Nevirapine in Uganda: A Prospective Cohort Study.
Chang JL; Tsai AC; Musinguzi N; Haberer JE; Boum Y; Muzoora C; Bwana M; Martin JN; Hunt PW; Bangsberg DR; Siedner MJ
Ann Intern Med; 2018 Aug; 169(3):146-155. PubMed ID: 29946683
[TBL] [Abstract][Full Text] [Related]
6. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.
Gutiérrez F; Navarro A; Padilla S; Antón R; Masiá M; Borrás J; Martín-Hidalgo A
Clin Infect Dis; 2005 Dec; 41(11):1648-53. PubMed ID: 16267739
[TBL] [Abstract][Full Text] [Related]
7. Quality of life and depression among HIV-infected patients receiving efavirenz- or protease inhibitor-based therapy in Senegal.
Poupard M; Ngom Gueye NF; Thiam D; Ndiaye B; Girard PM; Delaporte E; Sow PS; Landman R
HIV Med; 2007 Mar; 8(2):92-5. PubMed ID: 17352765
[TBL] [Abstract][Full Text] [Related]
8. Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review.
Muñoz-Moreno JA; Fumaz CR; Ferrer MJ; González-García M; Moltó J; Negredo E; Clotet B
AIDS Rev; 2009; 11(2):103-9. PubMed ID: 19529750
[TBL] [Abstract][Full Text] [Related]
9. Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks.
Mills AM; Antinori A; Clotet B; Fourie J; Herrera G; Hicks C; Madruga JV; Vanveggel S; Stevens M; Boven K;
HIV Med; 2013 Aug; 14(7):391-400. PubMed ID: 23298380
[TBL] [Abstract][Full Text] [Related]
10. HIV and mental illness in Malawi and the neuropsychiatric sequelae of efavirenz.
Drury A; Gleadow-Ware S; Gilfillan S; Ahrens J
Malawi Med J; 2018 Mar; 30(1):40-45. PubMed ID: 29868159
[TBL] [Abstract][Full Text] [Related]
11. Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects.
Leutscher PD; Stecher C; Storgaard M; Larsen CS
Scand J Infect Dis; 2013 Aug; 45(8):645-51. PubMed ID: 23427878
[TBL] [Abstract][Full Text] [Related]
12. Improvement of Depression and Anxiety After Discontinuation of Long- Term Efavirenz Treatment.
Mothapo KM; Schellekens A; van Crevel R; Keuter M; Grintjes-Huisman K; Koopmans P; van der Ven A
CNS Neurol Disord Drug Targets; 2015; 14(6):811-8. PubMed ID: 25808896
[TBL] [Abstract][Full Text] [Related]
13. A randomized crossover study to compare efavirenz and etravirine treatment.
Nguyen A; Calmy A; Delhumeau C; Mercier IK; Cavassini M; Fayet-Mello A; Elzi L; Genné D; Rauch A; Bernasconi E; Hirschel B;
AIDS; 2011 Jan; 25(1):57-63. PubMed ID: 21076278
[TBL] [Abstract][Full Text] [Related]
14. Treatment of depression with cyproheptadine.
Greenway SE; Pack AT; Greenway FL
Pharmacotherapy; 1995; 15(3):357-60. PubMed ID: 7667171
[TBL] [Abstract][Full Text] [Related]
15. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals.
Clifford DB; Evans S; Yang Y; Acosta EP; Goodkin K; Tashima K; Simpson D; Dorfman D; Ribaudo H; Gulick RM
Ann Intern Med; 2005 Nov; 143(10):714-21. PubMed ID: 16287792
[TBL] [Abstract][Full Text] [Related]
16. A review of trials investigating efavirenz-induced neuropsychiatric side effects and the implications.
Gaida R; Truter I; Grobler C; Kotze T; Godman B
Expert Rev Anti Infect Ther; 2016; 14(4):377-88. PubMed ID: 26900637
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.
; Carey D; Puls R; Amin J; Losso M; Phanupak P; Foulkes S; Mohapi L; Crabtree-Ramirez B; Jessen H; Kumar S; Winston A; Lee MP; Belloso W; Cooper DA; Emery S
Lancet Infect Dis; 2015 Jul; 15(7):793-802. PubMed ID: 25877963
[TBL] [Abstract][Full Text] [Related]
18. A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population.
Nelson M; Stellbrink HJ; Podzamczer D; Banhegyi D; Gazzard B; Hill A; van Delft Y; Vingerhoets J; Stark T; Marks S
AIDS; 2011 Jan; 25(3):335-40. PubMed ID: 21150563
[TBL] [Abstract][Full Text] [Related]
19. A systematic review of the psychiatric side-effects of efavirenz.
Kenedi CA; Goforth HW
AIDS Behav; 2011 Nov; 15(8):1803-18. PubMed ID: 21484283
[TBL] [Abstract][Full Text] [Related]
20. Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial.
Akhondzadeh S; Erfani S; Mohammadi MR; Tehrani-Doost M; Amini H; Gudarzi SS; Yasamy MT
J Clin Pharm Ther; 2004 Apr; 29(2):145-50. PubMed ID: 15068403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
